Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
Biochem Biophys Res Commun. 2010 Mar 19;393(4):688-93. doi: 10.1016/j.bbrc.2010.02.058. Epub 2010 Feb 18.
Induction of the major drug metabolizing enzyme CYP3A4 by xenobiotics contributes to the pronounced interindividual variability of its expression and often results in clinically relevant drug-drug interactions. It is mainly mediated by PXR, which regulates CYP3A4 expression by binding to several specific elements in the 5' upstream regulatory region of the gene. Induction itself shows a marked interindividual variability, whose underlying determinants are only partly understood. In this study, we investigated the role of nuclear receptor binding to PXR response elements in CYP3A4, as a potential non-genetic mechanism contributing to interindividual variability of induction. By in vitro DNA binding experiments, we showed that several nuclear receptors bind efficiently to the proximal promoter ER6 and distal xenobiotic-responsive enhancer module DR3 motifs. TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII further demonstrated dose-dependent repression of PXR-mediated CYP3A4 enhancer/promoter reporter activity in transient transfection in the presence and absence of the PXR inducer rifampin, while VDR showed this effect only in the absence of treatment. By combining functional in vitro characterization with hepatic expression analysis, we predict that TRalpha1, TRbeta1, COUP-TFI, and COUP-TFII show a strong potential for the repression of PXR-mediated activation of CYP3A4 in vivo. In summary, our results demonstrate that nuclear receptor binding to PXR response elements interferes with PXR-mediated expression and induction of CYP3A4 and thereby contributes to the interindividual variability of induction.
外源物质诱导主要药物代谢酶 CYP3A4 的表达,导致其表达的个体间差异显著,并常常引发具有临床意义的药物相互作用。该诱导主要由 PXR 介导,其通过结合 CYP3A4 基因上游调控区的特定元件来调节 CYP3A4 的表达。诱导本身存在明显的个体间差异,但其潜在决定因素尚不完全清楚。在这项研究中,我们研究了核受体与 PXR 反应元件结合在 CYP3A4 中的作用,作为导致诱导个体间差异的潜在非遗传机制。通过体外 DNA 结合实验,我们发现几种核受体能有效地与近端启动子 ER6 和远端外源响应增强子模块 DR3 结合。TRalpha1、TRbeta1、COUP-TFI 和 COUP-TFII 进一步证明,在存在和不存在 PXR 诱导剂利福平的情况下,它们在瞬时转染中能剂量依赖性地抑制 PXR 介导的 CYP3A4 增强子/启动子报告基因活性,而 VDR 仅在无处理的情况下显示出这种作用。通过将功能体外鉴定与肝表达分析相结合,我们预测 TRalpha1、TRbeta1、COUP-TFI 和 COUP-TFII 具有很强的潜力,能在体内抑制 PXR 介导的 CYP3A4 激活。总之,我们的研究结果表明,核受体与 PXR 反应元件的结合会干扰 PXR 介导的 CYP3A4 表达和诱导,从而导致诱导的个体间差异。